



**Center for Clinical Standards and Quality/Quality, Safety & Oversight Group**

---

**Notice to the Public of Limitation of the CLIA Certificate**

**Date** May 27, 2026  
**Title** Notice to the Public of Limitation of Legacy Md Medical Group Inc. of CLIA Certificate

**Notice to the Public of Limitation of Legacy Md Medical Group Inc.'s CLIA Certificate, CLIA #: 05D2078669**

On June 11, 2026, Legacy Md Medical Group Inc.'s CLIA certificate, located at 222 E Cole Blvd Calexico, CA 92231 will be limited for the analyte Free Thyroxine due to their failure to meet CLIA requirements.

The laboratory was notified on May 27, 2026.

When a laboratory's CLIA certificate is **limited**, it will not be permitted to perform any testing for the purpose of providing information for the diagnosis, prevention, treatment of any disease or impairment of, or the assessment of the health of human beings, in the testing area where it is limited. The laboratory may continue to perform parallel testing on specimens if needed to implement corrective actions; however, the laboratory may not report any test results during the period of limitation.

CMS is committed to patient safety and quality of care.

This action may still be appealable. To verify the certificate status and review the Statement of Deficiencies Report, visit [QCOR](#). You may also contact [FOIA\\_request@cms.hhs.gov](mailto:FOIA_request@cms.hhs.gov) for additional findings associated with these sanctions. To learn more about the CLIA, please visit <https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments>.